Home/Pipeline/CRCdx® RAS Mutation Detection Kit

CRCdx® RAS Mutation Detection Kit

Colorectal Cancer

ApprovedActive

Key Facts

Indication

Colorectal Cancer

Phase

Approved

Status

Active

Company

EntroGen

About EntroGen

EntroGen is a privately held, commercial-stage diagnostics company founded in 2008 and headquartered in Woodland Hills, California. The company has established a commercial footprint with its FDA-approved companion diagnostic for KRAS/NRAS mutations in colorectal cancer and is expanding its portfolio with RUO kits for minimal residual disease (MRD) and microsatellite instability (MSI). EntroGen's strategy centers on providing end-to-end, automated molecular diagnostic solutions to support personalized treatment decisions in oncology.

View full company profile

Therapeutic Areas

Oncology

Other Colorectal Cancer Drugs

Drug	Company	Phase	Status
CY-101 + Pembrolizumab	Cytovation	Phase 1/2	Initiate 1H-26
M9140	Merck KGaA	Phase 1/2	Active
Repositioned/Rerouted API	Reponex	Not Specified	Active
Leronlimab	CytoDyn	Phase 2	Phase in progress
EGFR inhibitor	Acellera	Pre-clinical	Hit Identification
Cannabics® RCC-33	CNBX Pharmaceuticals	Preclinical	Preparation of Pre-IND Meeting Package
VCR-036	Vicero Bio	Preclinical	Active
CBI-1214	Cartography Biosciences	Phase 1	Active
QL335	QLSF Biotherapeutics	Phase 1	Active
Colorectal Cancer Detection Partnership	Daisy Genomics	Research/Assay Development	Active
High Internalization ADC	Lytica Therapeutics	Preclinical	Active
Undisclosed Colorectal Program(s)	Tavanta Therapeutics	Phase 2	Active